Drug intelligence / Profile preview

Olinanoseal

Development stage: Phase 4
Lead developer: Olident
Modality: Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Olinanoseal (also referred to as OliNano SEAL) is a product evaluated in clinical studies for the treatment of dentin hypersensitivity. It is not a traditional pharmaceutical drug but rather a dental material or therapeutic agent designed to seal exposed dentin tubules and reduce sensitivity. The mechanism of action involves physically occluding the open tubules in dentin, thereby blocking stimuli that cause pain. There is no evidence that it acts via systemic pharmacological mechanisms[4][9].

Brand names: OliNano SEAL
Other names: OlinanosealOliNano SEAL

Beyond the preview

Go deeper on Olinanoseal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olinanoseal.

Explore the full profile